Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics said it expects near-term FDA feedback on reproxalap after a third complete response letter tied to efficacy questions. The update highlights ongoing regulatory risk for the dry eye disease candidate and suggests continued uncertainty around approval timing. The news is company-specific and likely to affect ALDX shares more than the broader sector.

Analysis

Aldeyra Therapeutics said it expects near-term FDA feedback on reproxalap after a third complete response letter tied to efficacy questions. The update highlights ongoing regulatory risk for the dry eye disease candidate and suggests continued uncertainty around approval timing. The news is company-specific and likely to affect ALDX shares more than the broader sector.